‘No Turning Back’ On Regulatory Changes at UK MHRA
Industry’s Role Praised By Innovation Minister
Executive Summary
The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.
You may also be interested in...
Pandemic Clinical Trials Need More Top-Down Control, Gottlieb Says
Ex-FDA commissioner offers British platform trials as examples of research done right, as he worries about studies that aren’t going to yield ‘definitive information’ crowding out trials that are more compelling and for more promising COVID-19 therapeutics.
UK Presents New Licensing Pathway For Innovative Drugs
A “powerful new vision” for the post-Brexit UK regulatory framework was unveiled at a conference organized by the BioIndustry Association and the medicines regulator, the MHRA.
'Don't Compromise The Pharma Innovation System,' Says Outgoing IFPMA Head Thomas Cueni
Thomas Cueni is stepping down after seven years at the helm of the International Federation of Pharmaceutical Manufacturers and Associations. In an interview with the Pink Sheet ahead of his retirement, he reflects on the proposed pandemic treaty, what still needs to be done to ensure equitable access to medicines, the importance of tackling AMR, moves towards regulatory reliance – and what his post-IFPMA life might look like.